A new once-daily pill called solengepras shows promise for Parkinson's disease by taking a different approach than traditional treatments. Instead of boosting dopamine like most Parkinson's drugs, solengepras targets a brain receptor called GPR6 to restore balance in movement circuits. In Phase 2 trials, patients experienced meaningful reductions in daily 'OFF time' - periods when motor symptoms worsen despite medication. The drug also improved sleep disturbances, which often amplify Parkinson's symptoms. This represents a shift from single-chemical fixes to systems-level treatments that address the complex imbalances in Parkinson's disease. The drug is now being tested in a larger Phase 3 trial involving 330 patients.
